Piper Sandler analyst Matt O’Brien raised the firm’s price target on Sight Sciences (SGHT) to $5 from $4 and keeps a Neutral rating on the shares. The firm notes the company reported Q3 results that beat expectations on the top and bottom-line and raised its full year 2025 revenue guidance to $76M-$78M, or by about $3.0M at the midpoint. Piper was pleased to see the outperformance in the surgical glaucoma segment as the company was able to grow that business +6% year-over-year in the quarter, which was much better than expected.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Balanced Outlook: Hold Rating on Sight Sciences Amid Strong Performance and Uncertainties
- Sight Sciences Raises Revenue Guidance Amid Strategic Shifts
- Sight Sciences reports Q3 EPS (16c), consensus (26c)
- Sight Sciences Announces Key Management Changes
- Sight Sciences’ Latest Study on OMNI 3.0 System: A Potential Game-Changer for Glaucoma Treatment